These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3197751)

  • 21. Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm.
    Wigley FM; Wise RA; Malamet R; Scott TE
    Arthritis Rheum; 1987 Mar; 30(3):281-6. PubMed ID: 2952125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study.
    Baart de la Faille H; van Weelden H; Banga JD; van Kesteren RG
    Arch Dermatol Res; 1986; 279(1):3-7. PubMed ID: 3545103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.
    Bounameaux HM; Hellemans H; Verhaeghe R; Dequeker J
    J Cardiovasc Pharmacol; 1984; 6(5):975-6. PubMed ID: 6209510
    [No Abstract]   [Full Text] [Related]  

  • 24. Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon.
    Codella O; Caramaschi P; Olivieri O; Perbellini L; Perbellini A; Bambara LM; Corrocher R; De Sandre G
    Angiology; 1989 Feb; 40(2):114-21. PubMed ID: 2644876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
    Stranden E; Roald OK; Krohg K
    Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
    Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ketanserin versus nifedipine in secondary Raynaud's phenomenon.
    Kirch W; Linder HR; Hutt HJ; Ohnhaus EE; Mahler F
    Vasa; 1987; 16(1):77-80. PubMed ID: 3554811
    [No Abstract]   [Full Text] [Related]  

  • 28. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon?
    Brouwer RM; Wenting GJ; Visser W; Schalekamp MA
    Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817
    [No Abstract]   [Full Text] [Related]  

  • 29. [New treatments for Raynaud's syndrome].
    Bellucci S; Kedra W; Ajzenberg N; Tobelem G; Caen J
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):103-7. PubMed ID: 3290833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist.
    Igarashi M; Okuda T; Oh-i T; Koga M
    J Dermatol; 2000 Oct; 27(10):643-50. PubMed ID: 11092268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation.
    Malamet R; Wise RA; Ettinger WH; Wigley FM
    Am J Med; 1985 Apr; 78(4):602-8. PubMed ID: 3157318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raynaud's phenomenon. An update.
    Coffman JD
    Hypertension; 1991 May; 17(5):593-602. PubMed ID: 2022404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.
    Francis JL; Roath OS; Challenor VF; Waller DG
    Br J Clin Pharmacol; 1988 Jun; 25(6):751-4. PubMed ID: 3203045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
    Seibold JR; Terregino CA
    J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonin and Raynaud's phenomenon.
    Seibold JR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S95-8. PubMed ID: 2412070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute effects and mechanism of action of ketanserin in patients with primary Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):868-76. PubMed ID: 1694908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
    Seibold JR; Jageneau AH
    Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
    Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
    Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
    Pola P; Tondi P; Serricchio M; Favuzzi A; Gerardino L
    Angiology; 1993 Feb; 44(2):123-8. PubMed ID: 8434805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional intravenous ketanserin and guanethidine therapy in Raynaud's phenomenon.
    Caputi CA; De Carolis G; Tomasetti C
    Angiology; 1991 Jun; 42(6):473-80. PubMed ID: 2042796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.